In this issue of Clinical Cancer Research, Naik and colleagues (1) provide the rationale for a synthetic lethal therapy theoretically based on targeted inhibition of vascular endothelial growth factor receptor-1 (VEGFR1)-mediated kinase activity in Wnt/β-catenin-addicted human colorectal cancer (CRC) cells (Fig. 1). Wnt is a cysteine-rich secreted molecule and prototype of a 19-member family of proteins. It activates target genes primarily through binding and stabilization of the Frizzled/LRP6 membrane receptor complex. This complex sequesters cytoplasmic Axin thus preventing it from mediating the ubiquitination and degradation of β-catenin. Stable β-catenin is phosphorylated and translocated to the nucleus, where it targets the TCF/LEF family of transcription factors and promotes expression of genes that regulate cell proliferation and cell polarity (2). A significant proportion of CRCs have an activating mutation in the Wnt/β-catenin pathway resulting in the abnormal expression of proliferation mediators and growth factors (e.g., C-myc and VEGF; ref. 3).

Naik and colleagues (1) expose a direct link between VEGFR1 function and the Wnt/β-catenin signaling pathway in CRC cells. To determine this linkage, they developed a Wnt/β-catenin screening protocol conceptually based on the phenomenon of synthetic lethality (4). The authors used a series of small inhibitory RNA (siRNA) and short hairpin RNA (shRNA) panels to interrogate a human embryonic kidney cell line (STF293) bearing a Wnt/β-catenin-responsive reporter gene. RNA interference protocols have been introduced recently as synthetic lethal screens and have already begun to uncover other unexpected linkages between genes and survival pathways that show promise for therapeutic intervention (4, 5). Notably, this technique uncovers functional weaknesses of mutations specifically mediating survival of cancer cells, thus allowing highly specific pharmacological targeting strategies.

The discoveries made by Naik and colleagues (1) shed new light on the complexities of VEGF-receptor signaling and function. VEGF binds to both VEGFR1 and VEGFR2, the primary VEGF receptors involved with angiogenesis and vasculogenesis. VEGFR1 has weak tyrosine kinase activity compared with VEGFR2. Interestingly, VEGF binds to VEGFR2 with weaker affinity than to VEGFR1, but it results in far stronger VEGFR2 tyrosine kinase activity (6). The biologic relevance of the unique and reciprocal characteristics of these two receptors remains to be fully understood. We have recently reported that VEGF-dependent tumor angiogenesis involves the inverse and reciprocal regulation of VEGFR1 and VEGFR2 (7). VEGFR2 undergoes endocytosis, nuclear translocation, and down-regulation via ubiquitination in response to VEGF-induced signaling through the JNK/c-Jun pathway. In contrast, VEGF/VEGFR-1 signals through the Akt/ERK pathway to inhibit constitutive ubiquitination and induce rapid VEGFR1 protein accumulation in endothelial cells. Surprisingly, VEGFR1 is primarily localized intracellularly in endothelial cells (7, 8). VEGFR1 is strongly expressed in CRC cells, where it also shows an intracellular localization (9). In light of the current observations by Naik and colleagues on the importance of VEGFR1 for the survival of CRC cells, these results bring to light the challenges in development of therapeutic agents targeting VEGFR1, particularly antibodies designed to inhibit VEGFR1 function.

Naik and colleagues (1) identify VEGFR1, among others, as a synthetic lethal partner to the Wnt-signaling pathway. In confirmation of the screen data, VEGFR tyrosine kinase inhibitors were effective at inhibiting growth of Wnt/β-catenin-addicted CRC cells, but not control cells bearing normal Wnt function. Does this new observation fit in with any currently recognized VEGF receptor-related mechanism? VEGFR2 is primarily expressed on endothelial cells, whereas VEGFR1 has been detected...
on a variety of normal cell types but also on tumor cells including, notably, CRC cells (9). In endothelial cells, the prosurvival effect of VEGF depends on VEGFR1-mediated up-regulation of Bcl-2 and inhibition of caspase-3 activity (7). Until Naik and colleagues showed that inhibition of VEGFR1 leads to cell death via direct disruption of the Wnt/β-catenin survival pathway, the Wnt/β-catenin pathway was not known to be directly related to signaling by any VEGF receptor. However, Wnt has been shown to up-regulate VEGF secretion in CRC cells in vitro (10). We perhaps begin to glimpse a possible autocrine survival strategy involving elements of a network traditionally thought to be primarily related to angiogenesis but exploited here by Wnt/β-catenin-addicted CRC cells.

Current clinical studies of angiogenesis inhibitors, particularly VEGF-targeted agents, have lead to variable results. Two classes of therapeutic approach warrant discussion: antibody-based drugs and nonpeptidic small molecule inhibitors (11). The main benefit of antibody-based therapies is clear, in that they are highly specific and, therefore, as a class, may have fewer off-target effects or clinical side effects than other drug types. Bevacizumab, a humanized monoclonal anti-VEGF antibody has been approved by the U.S. Food and Drug Administration (FDA) after showing efficacy in combination with traditional chemotherapeutics (11), as well as when studied as a single agent in select cancers. However, for the inhibition of an intracellular target, antibodies suffer from physical chemistry, being too large to enter cells. If the very recent observations of VEGFR1 intracellular localization in endothelial cells and CRC cells are confirmed in vivo, anti-VEGFR1 antibodies will likely not be effective in CRC, unless they act through other cellular components of the tumor microenvironment (e.g., cancer-associated fibroblasts or immune cells). In contrast, small molecule tyrosine kinase inhibitors may achieve direct inhibition of intracellular kinase activity, as shown by Naik and colleagues. These low molecular weight drugs are readily modifiable to increase bioavailability, specificity, and efficacy. However, off-target effects have been frequently observed with tyrosine kinase inhibitors, which hinders one’s ability to clearly understand their exact mechanisms of action.

For high specificity, we may ultimately seek gene-silencing methodologies for effective and precise inhibition of VEGFR-1 pathway function. Some questions do exist about off-target effects of RNA-based gene-silencing methodologies, although providentially these effects may be anti-angiogenic in their own right (12). The stringency of nucleotide complementarity is high, however, tissue-specific delivery is inherently absent in these molecules. Fortunately, RNA interference (RNAi) is compatible with a number of modifiable clinically relevant and specific delivery systems, in particular viral packaging and liposome encapsulation. Notably, it is conceptually attractive to be able to identify intimately reliant tumor cell survival pathways using the same technology and mechanism, in this instance RNAi, which can be directly translated in vivo and potentially into clinical settings.

Everything being equal, inhibition of VEGF pathways is expected to attenuate angiogenesis and impair tumor growth. However, clinical experience is showing that this is frequently not the case. In light of the data described by Naik and colleagues (1), rational treatment with anti-VEGFR-1 antibodies may require the detailed study of cellular localization of the target receptors, as several receptors that are targets for therapy have been found to have intracellular functions independent of their kinase activities (13). Naik and colleagues (1) perhaps provide one additional explanation for the observed variable effects of anti-VEGFR therapy, by linking the effect of VEGFR1 inhibition to the presence and/or absence of aberrant Wnt/β-catenin signaling. These exciting new observations reveal a new facet for selectivity of antitumor agents masquerading as anti-angiogenic agents, and underline the urgent need for deeper understanding of the biology of VEGF receptor signaling.

**Disclosure of Potential Conflicts of Interest**

L. Ellis, consultant, Schering-Plough; commercial research grant, Sanofi-Aventis, Imclone; advisory board, Genentech/Roche, Amgen, AstraZeneca.
References


Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/β-catenin Crosstalk Leads to Tumor Cell Death

Benjamin D. Zeitlin, Lee M. Ellis and Jacques E. Nör


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/24/7453

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/12/15/15.24.7453.DC1

Cited articles
This article cites 12 articles, 2 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/24/7453.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/15/24/7453.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.